Logo

Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Share this
Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Shots:

  • The first patient has been dosed in a P-III clinical study evaluating the efficacy and safety of BAT2206 vs reference Stelara in ~ 472 patients with moderately to severely PsO
  • BAT2206 represents the 4th biosimilar of Bio-Thera's portfolio to enter P-III study. The advancement of BAT2206 in P-III study demonstrates company’s commitment to develop biosimilars to expand patient access at lower costs
  • Bio-Thera Solutions is developing additional proposed biosimilars- including a bevacizumab biosimilar and a tocilizumab biosimilar that have completed global P- III clinical trials. The company is also pursuing biosimilar versions of golimumab- mepolizumab- and dupilumab

  Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions